Do you think the delivery system is enough to make it an investment? Or that the market will be large enough that it does not matter?
ZIOP uses an IL-12 via oral route and is further along in the clinic. Other intratumoral (intralesional) agents produce immunotheraputic action as well, such as PV-10 currently in phase 3. No reference available but I also recall seeing other drug candidates in preclinical showing the same effect where there is a combination of ablative and immunotheraputic effect.
If one believes that the intralesional IL-12 is worthwhile as more than a trade, one would also have to look at several other therapies including some that are closer to approval.
News 
Market Data 
Discover 
